MetaVia Inc. reported its third quarter 2026 financial results, highlighting positive interim Phase 1 Part 3B data for its liver drug candidate, DA-1726. The company observed a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at 16 weeks, supporting plans for a Phase 2 study in up to 150 MetALD and ALD patients in the second half of 2027.
Bullish
🤖 70%
The Q3 2026 report (quarter ended September 30, 2026) leads with strong Phase 1 Part 3B interim data for DA-1726: a 68.1% placebo-adjusted liver fat reduction at 16 weeks, all five steatosis patients reaching MRI-PDFF below 5%, and 13.5% placebo-adjusted weight loss. This supports a 48-week Phase 2 study in up to 150 MetALD/ALD subjects targeted for the second half of 2027, a meaningful pipeline advance for a clinical-stage biotech. The financials themselves show only higher burn (operating expenses up to ~$4.7 million in Q3 from ~$3.5 million a year earlier) with no revenue, which is routine
Catalysts
- ▲ Positive Phase 1 Part 3B interim data for DA-1726: 68.1% placebo-adjusted liver fat reduction and 13.5% placebo-adjusted weight loss at ~16 weeks
- ▲ Planned 48-week Phase 2 study in up to 150 MetALD/ALD subjects targeted for the second half of 2027
Risk Factors
- ▼ Interim results cover only five participants with baseline steatosis, a very small sample that full Phase 1 data in Q1 2027 may not confirm
- ▼ Operating expenses rose to approximately $4.7 million in Q3 2026 from approximately $3.5 million a year earlier, increasing cash burn with no revenue